Celldex Therapeutics develops therapeutic antibodies for various diseases. Drug candidates target inflammatory, allergic, autoimmune, and other diseases. CDX-0159 is a Phase II monoclonal antibody that targets KIT receptor. The company collaborates with Yale University. Incorporated in 1983, Celldex is headquartered in New Jersey.
Indicator | Value |
---|---|
PER | 100.0 |
EV/EBITDA | 100.0 |
Price/Free Cash Flow' | 100.0 |
ROIC | -% |
Net Debt/EBITDA | 0.1 |